secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001297184-26-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal
--------------------------------------------------------------------------------

- Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.
- Upfront payment of $2 million; potential milestones up to $14 million (development) and $75 million (sales).
- Royalty payments capped at $7.5 million per year and $60 million total; Hanxin will also pay Amphastar royalties on certain sales.
- Related-party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own a majority of Hanxin.
- US ACTH market exceeded $684 million in 2024; AMP-110 aims for inflammatory and autoimmune conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/0001297184-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/amph-20260106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer